References

therapeutic

Южно-Российский журнал терапевтической практики

South Russian Journal of Therapeutic Practice

2712-8156

РостГМУ

10.21886/2712-8156-2022-3-3-7-16

therapeutic-257

Research Article

ОБЗОРЫ

REVIEWS

Реверсия и ремиссия — перспективные цели для больных сахарным диабетом 2 типа

Reversion and remission are promising targets for patients with type 2 diabetes mellitus

https://orcid.org/0000-0003-1510-9204

Канорский

С. Г.

Kanorskii

S. G.

Канорский Сергей Григорьевич, доктор медицинских наук, проф., заведующий кафедрой терапии №2 факультета повышения квалификации и профессиональной переподготовки

Краснодар

Sergey G. Kanorskii, Dr. Sci. (Med.), Prof., Head of the Department of Therapy №2, Faculty of Advanced Training and Professional Retraining

Krasnodar

kanorskysg@mail.ru

ФГБОУ ВО «Кубанский государственный медицинский университет» Минздрава РоссииРоссияKuban State Medical UniversityRussian Federation

2022

01092022

33716

2022

Канорский С.Г.

Kanorskii S.G.

This work is licensed under a Creative Commons Attribution 4.0 License.

https://www.therapeutic-j.ru/jour/article/view/257

Снижение массы тела и изменение образа жизни способны привести к обратному развитию патофизиологических процессов, лежащих в основе сахарного диабета 2 типа, в том числе к достижению ремиссии болезни. Проведены поиск и анализ 9109 литературных источников из баз данных Scopus, Web of Science, PubMed/MedLine, The CochraneLibrary по ключевым словам «diabetes remission», «diabetes reversal», «bariatric surgery», «very low-calorie diet», «low carbohydrate diet». В обзоре представлены и критически оценены современные возможности достижения ремиссии сахарного диабета 2 типа с помощью бариатрической хирургии, медикаментозных препаратов, очень низкокалорийной и низкоуглеводной диет, физических упражнений.

Weight loss and lifestyle changes can reverse the pathophysiological processes underlying type 2 diabetes, including achieving remission of the disease. A search and analysis of 9109 literature sources from the Scopus, Web of Science, PubMed/ MedLine, The CochraneLibrary databases was carried out for the keywords «diabetes remission», «diabetes reversal», «bariatric surgery», «very low-calorie diet», «low carbohydrate diet». The review presents and critically evaluates the current possibilities of achieving remission of type 2 diabetes mellitus with the help of bariatric surgery, medications, very low-calorie and lowcarbohydrate diets, and exercise.

обзорсахарный диабет 2 типаремиссиядиетамедикаментозное лечениебариатрическая хирургия

reviewtype 2 diabetesremissiondietdrug treatmentbariatric surgery

References1

Aras M, Tchang BG, Pape J. Obesity and Diabetes. Nurs Clin North Am. 2021;56(4):527-541. DOI: 10.1016/j.cnur.2021.07.008.

Lima JEBF, Moreira NCS, Sakamoto-Hojo ET. Mechanisms underlying the pathophysiology of type 2 diabetes: From risk factors to oxidative stress, metabolic dysfunction, and hyperglycemia. Mutat Res Genet Toxicol Environ Mutagen. 2022;874-875:503437. DOI: 10.1016/j.mrgentox.2021.503437.

Rahman MS, Hossain KS, Das S, Kundu S, Adegoke EO, Rahman MA, et al. Role of Insulin in Health and Disease: An Update. Int J Mol Sci. 2021;22(12):6403. DOI: 10.3390/ijms22126403.

Zokaei A, Ziapour A, Khanghahi ME, Lebni JY, Irandoost SF, Toghroli R, et al. Investigating high blood pressure, type-2 diabetes, dislipidemia, and body mass index to determine the health status of people over 30 years. J Educ Health Promot. 2020;9:333. DOI: 10.4103/jehp.jehp_514_20.

Weir GC. Glucolipotoxicity, β-Cells, and Diabetes: The Emperor Has No Clothes. Diabetes. 2020;69(3):273-278. DOI: 10.2337/db19-0138.

Coles B, Zaccardi F, Ling S, Davies MJ, Samani NJ, Khunti K. Cardiovascular events and mortality in people with and without type 2 diabetes: An observational study in a contemporary multi-ethnic population. J Diabetes Investig. 2021;12(7):1175-1182. DOI: 10.1111/jdi.13464.

American Diabetes Association Professional Practice Committee, Draznin B, Aroda VR, Bakris G, Benson G, Brown FM, et al. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S125-S143. DOI: 10.2337/dc22-S009.

American Diabetes Association Professional Practice Committee. 10. Cardiovascular Disease and Risk Management: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S144-S174. DOI: 10.2337/dc22-S010.

Singla R, Gupta G, Dutta D, Raizada N, Aggarwal S. Diabetes reversal: Update on current knowledge and proposal of prediction score parameters for diabetes remission. Diabetes Metab Syndr. 2022;16(4):102452. DOI: 10.1016/j.dsx.2022.102452.

Buse JB, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, et al. How do we define cure of diabetes? Diabetes Care. 2009;32(11):2133-2135. DOI: 10.2337/dc09-9036.

Nagi D., Hambling C., Taylor R. Remission of type 2 diabetes: A position statement from the Association of British Clinical Diabetologists (ABCD) and the Primary Care Diabetes Society (PCDS). Br J Diabetes. 2019;19:73-76. DOI: 10.15277/bjd.2019.221.

Kalra S, Singal A, Lathia T. What’s in a Name? Redefining Type 2 Diabetes Remission. Diabetes Ther. 2021;12(3):647-654. DOI: 10.1007/s13300-020-00990-z.

Riddle MC, Cefalu WT, Evans PH, Gerstein HC, Nauck MA, Oh WK, et al. Consensus Report: Definition and Interpretation of Remission in Type 2 Diabetes. Diabetes Care. 2021;44(10):2438-2444. DOI: 10.2337/dci21-0034.

Captieux M, Fleetwood K, Kennon B, Sattar N, Lindsay R, Guthrie B, et al.; Scottish Diabetes Research Network Epidemiology Group. Epidemiology of type 2 diabetes remission in Scotland in 2019: A cross-sectional populationbased study. PLoS Med. 2021;18(11):e1003828. DOI: 10.1371/journal.pmed.1003828.

Vinik A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. Clin Ther. 2007;29 Spec No:1236-53. PMID: 18046925.

Hallberg SJ, Gershuni VM, Hazbun TL, Athinarayanan SJ. Reversing Type 2 Diabetes: A Narrative Review of the Evidence. Nutrients. 2019;11(4):766. DOI: 10.3390/nu11040766.

Rubino F, Nathan DM, Eckel RH, Schauer PR, Alberti KG, Zimmet PZ, et al.; Delegates of the 2nd Diabetes Surgery Summit. Metabolic Surgery in the Treatment Algorithm for Type 2 Diabetes: A Joint Statement by International Diabetes Organizations. Diabetes Care. 2016;39(6):861-877. DOI: 10.2337/dc16-0236.

Larraufie P, Roberts GP, McGavigan AK, Kay RG, Li J, Leiter A, Melvin A, et al. Important Role of the GLP-1 Axis for Glucose Homeostasis after Bariatric Surgery. Cell Rep. 2019;26(6):1399-1408.e6. DOI: 10.1016/j.celrep.2019.01.047.

Anhê FF, Varin TV, Schertzer JD, Marette A. The Gut Microbiota as a Mediator of Metabolic Benefits after Bariatric Surgery. Can J Diabetes. 2017;41(4):439-447. DOI: 10.1016/j.jcjd.2017.02.002.

Akalestou E, Miras AD, Rutter GA, le Roux CW. Mechanisms of Weight Loss After Obesity Surgery. Endocr Rev. 2022;43(1):19- 34. DOI: 10.1210/endrev/bnab022.Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93-102. DOI: 10.1007/s11695-012-0802-1.

Arterburn DE, Bogart A, Sherwood NE, Sidney S, Coleman KJ, Haneuse S, et al. A multisite study of long-term remission and relapse of type 2 diabetes mellitus following gastric bypass. Obes Surg. 2013;23(1):93-102. DOI: 10.1007/s11695-012-0802-1.

Sjöström L, Peltonen M, Jacobson P, Ahlin S, Andersson- Assarsson J, Anveden Å, et al. Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications. JAMA. 2014;311(22):2297-2304. DOI: 10.1001/jama.2014.5988.

Salminen P, Grönroos S, Helmiö M, Hurme S, Juuti A, Juusela R, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Rouxen-Y Gastric Bypass on Weight Loss, Comorbidities, and Reflux at 10 Years in Adult Patients With Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA Surg. 2022 Jun 22:e222229. DOI: 10.1001/jamasurg.2022.2229. Online ahead of print.

Murphy R, Plank LD, Clarke MG, Evennett NJ, Tan J, Kim DDW, et al. Effect of Banded Roux-en-Y Gastric Bypass Versus Sleeve Gastrectomy on Diabetes Remission at 5 Years Among Patients With Obesity and Type 2 Diabetes: A Blinded Randomized Clinical Trial. Diabetes Care. 2022;45(7):1503-1511. DOI: 10.2337/dc21-2498.

Chang SH, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. JAMA Surg. 2014;149(3):275-287. DOI: 10.1001/jamasurg.2013.3654.

Alqunai MS, Alrashid FF. Bariatric surgery for the management of type 2 diabetes mellitus-current trends and challenges: a review article. Am J Transl Res. 2022;14(2):1160-1171. eCollection 2022.

Alalwan AA, Friedman J, Park H, Segal R, Brumback B, Hartzema A. Comparative Safety of Sleeve Gastrectomy and Roux-en-Y: A Propensity Score Analysis. World J Surg. 2022 Jul 15. DOI: 10.1007/s00268-022-06664-0. Online ahead of print.

American Diabetes Association Professional Practice Committee. 8. Obesity and Weight Management for the Prevention and Treatment of Type 2 Diabetes: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1): S113–S124. DOI: 10.2337/dc22-S010.

Wang L, Li X, Wang Z, Bancks MP, Carnethon MR, Greenland P, et al. Trends in Prevalence of Diabetes and Control of Risk Factors in Diabetes Among US Adults, 1999-2018. JAMA. 2021;326(8):704-716. DOI:10.1001/jama.2021.9883.

Kramer CK, Zinman B, Retnakaran R. Short-term intensive insulin therapy in type 2 diabetes mellitus: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 2013;1(1):28-34. DOI: 10.1016/S2213-8587(13)70006-8.

Wang H, Kuang J, Xu M, Gao Z, Li Q, Liu S, et al. Predictors of Long-Term Glycemic Remission After 2-Week Intensive Insulin Treatment in Newly Diagnosed Type 2 Diabetes. J Clin Endocrinol Metab. 2019;104(6):2153-2162. DOI: 10.1210/jc.2018-01468.

Jacob S, Rabbia M, Meier MK, Hauptman J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. Diabetes Obes Metab. 2009;11(4):361-371. DOI: 10.1111/j.1463-1326.2008.00970.x.

Brown E, Wilding JPH, Barber TM, Alam U, Cuthbertson DJ. Weight loss variability with SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes mellitus and obesity: Mechanistic possibilities. Obes Rev. 2019;20(6):816-828. DOI: 10.1111/obr.12841.

Rubino DM, Greenway FL, Khalid U, O’Neil PM, Rosenstock J, Sørrig R, et al.; STEP 8 Investigators. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022;327(2):138-150. DOI: 10.1001/jama.2021.23619.

Nauck MA, Meier JJ. Incretin hormones: Their role in health and disease. Diabetes Obes Metab. 2018;20 Suppl 1:5-21. DOI: 10.1111/dom.13129.

Davies M, Færch L, Jeppesen OK, Pakseresht A, Pedersen SD, Perreault L, et al.; STEP 2 Study Group. Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, doubleblind, double-dummy, placebo-controlled, phase 3 trial. Lancet. 2021;397(10278):971-984. DOI: 10.1016/S0140-6736(21)00213-0.

Rosenstock J, Wysham C, Frías JP, Kaneko S, Lee CJ, Fernández Landó L, et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021;398(10295):143-155. DOI: 10.1016/S0140-6736(21)01324-6.

Frías JP, Davies MJ, Rosenstock J, Pérez Manghi FC, Fernández Landó L, Bergman BK, et al.; SURPASS-2 Investigators. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. N Engl J Med. 2021;385(6):503-515. DOI: 10.1056/NEJMoa2107519.

Churuangsuk C, Hall J, Reynolds A, Griffin SJ, Combet E, Lean MEJ. Diets for weight management in adults with type 2 diabetes: an umbrella review of published metaanalyses and systematic review of trials of diets for diabetes remission. Diabetologia. 2022;65(1):14-36. DOI: 10.1007/s00125-021-05577-2.

Gregg EW, Chen H, Wagenknecht LE, Clark JM, Delahanty LM, Bantle J, et al.; Look AHEAD Research Group. Association of an intensive lifestyle intervention with remission of type 2 diabetes. JAMA. 2012;308(23):2489-2496. DOI: 10.1001/jama.2012.67929.

Look AHEAD Research Group; Look AHEAD Research Group:, Wing RR, Bray GA, Cassidy-Begay M, Clark JM, Coday M, Egan C, et al. Effects of Intensive Lifestyle Intervention on All-Cause Mortality in Older Adults With Type 2 Diabetes and Overweight/Obesity: Results From the Look AHEAD Study. Diabetes Care. 2022;45(5):1252-1259. DOI: 10.2337/dc21-1805.

Lean MEJ, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Durability of a primary care-led weightmanagement intervention for remission of type 2 diabetes: 2-year results of the DiRECT open-label, cluster-randomised trial. Lancet Diabetes Endocrinol. 2019;7(5):344-355. DOI: 10.1016/S2213-8587(19)30068-3.

Taheri S, Zaghloul H, Chagoury O, Elhadad S, Ahmed SH, El Khatib N, et al. Effect of intensive lifestyle intervention on bodyweight and glycaemia in early type 2 diabetes (DIADEM-I): an open-label, parallel-group, randomised controlled trial. Lancet Diabetes Endocrinol. 2020;8(6):477-489. DOI: 10.1016/S2213-8587(20)30117-0.

Thom G, Messow CM, Leslie WS, Barnes AC, Brosnahan N, McCombie L, et al. Predictors of type 2 diabetes remission in the Diabetes Remission Clinical Trial (DiRECT). Diabet Med. 2021;38(8):e14395. DOI: 10.1111/dme.14395.

Dambha-Miller H, Day AJ, Strelitz J, Irving G, Griffin SJ. Behaviour change, weight loss and remission of Type 2 diabetes: a community-based prospective cohort study. Diabet Med. 2020;37(4):681-688. DOI: 10.1111/dme.14122.

Mathew R. Rammya Mathew: Liquid diets offer promise, but we still need upstream solutions. BMJ. 2019;364:k5340. DOI: 10.1136/bmj.k5340.

Taylor R, Al-Mrabeh A, Sattar N. Understanding the mechanisms of reversal of type 2 diabetes. Lancet Diabetes Endocrinol. 2019;7(9):726-736. DOI: 10.1016/S2213-8587(19)30076-2.

Feinman RD, Pogozelski WK, Astrup A, Bernstein RK, Fine EJ, Westman EC, et al. Dietary carbohydrate restriction as the first approach in diabetes management: critical review and evidence base. Nutrition. 2015;31(1):1-13. DOI: 10.1016/j.nut.2014.06.011.

Jayedi A, Zeraattalab-Motlagh S, Jabbarzadeh B, Hosseini Y, Jibril AT, Shahinfar H, et al. Dose-dependent effect of carbohydrate restriction for type 2 diabetes management: a systematic review and dose-response meta-analysis of randomized controlled trials. Am J Clin Nutr. 2022;116(1):40-56. DOI: 10.1093/ajcn/nqac066.

Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2018;41(12):2669-2701. DOI: 10.2337/dci18-0033.

Huebschmann AG, Glasgow RE, Leavitt IM, Chapman K, Rice JD, Lockhart S, et al. Integrating a physical activity coaching intervention into diabetes care: a mixed-methods evaluation of a pilot pragmatic trial. Transl Behav Med. 2022;12(4):601-610. DOI: 10.1093/tbm/ibac014.

Franz MJ, MacLeod J, Evert A, Brown C, Gradwell E, Handu D, et al. Academy of Nutrition and Dietetics Nutrition Practice Guideline for Type 1 and Type 2 Diabetes in Adults: Systematic Review of Evidence for Medical Nutrition Therapy Effectiveness and Recommendations for Integration into the Nutrition Care Process. J Acad Nutr Diet. 2017;117(10):1659-1679. DOI: 10.1016/j.jand.2017.03.022.

Bittel AJ, Bittel DC, Mittendorfer B, Patterson BW, Okunade AL, Abumrad NA, et al. A Single Bout of Premeal Resistance Exercise Improves Postprandial Glucose Metabolism in Obese Men with Prediabetes. Med Sci Sports Exerc. 2021;53(4):694-703. DOI: 10.1249/MSS.0000000000002538.

Eichner NZM, Gaitán JM, Gilbertson NM, Khurshid M, Weltman A, Malin SK. Postprandial augmentation index is reduced in adults with prediabetes following continuous and interval exercise training. Exp Physiol. 2019;104(2):264-271. DOI: 10.1113/EP087305.

Caulfield B, Crowe L, Coughlan G, Minogue C. Clinical application of neuromuscular electrical stimulation induced cardiovascular exercise. Annu Int Conf IEEE Eng Med Biol Soc. 2011;2011:3266-3269. DOI: 10.1109/IEMBS.2011.6090887.

Action to Control Cardiovascular Risk in Diabetes Study Group, Gerstein HC, Miller ME, Byington RP, Goff DC Jr, Bigger JT, Buse JB, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545-2559. DOI: 10.1056/NEJMoa0802743.

The authors declare that there are no conflicts of interest present.